STAT NewsOriginal article
STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
Phase 3negativeNegative
AI Analysis
Summary
An experimental Novartis drug for a rare neuromuscular condition failed to meet its primary endpoint in a pivotal study, failing to improve muscle function. Novo Nordisk also experienced a setback mentioned in the brief news summary.
Clinical Trial Data
Phase
pivotal
Primary Endpoint
Not Met
Outcome Details
failed to improve muscle function in pivotal study
Importance:7/10
Sentiment:
-0.80
trial failureneuromuscular diseaseNovartisNovo Nordisknegative data
Read the original article
Published by STAT News on September 8, 2026 1:26 PM